BBOT vs C · $610.4M cap vs P/E 16, rev $85.22B
BridgeBio Oncology Therapeutics, Inc. (BBOT) versus Citigroup Inc. (C) — a side-by-side from cached financials, not a winner call.
BridgeBio Oncology Therapeutics, Inc. (BBOT) is a biotechnology company listed on NASDAQ.
Citigroup Inc. (C) is a banks - diversified company listed on US.
BBOT does not have a complete income-statement cache yet.
Latest reported C revenue for 2025-12-31 was $85.22B. Net income was $14.31B. Revenue was up 5.0% from 2024-12-31 to 2025-12-31. C currently screens at market cap $214.73B and trailing P/E 15.5.
BBOT currently screens at market cap $610.4M. C currently screens at market cap $214.73B and trailing P/E 15.5.
Not investment advice. Open the BBOT and C stock pages for the full models.
Not investment advice.